	US 12,433,944 B2
	Vaccine composition
Sumi Biswas, Oxford (GB); Jing Jin, Oxford (GB); Rebecca Alice Dabbs, Oxford (GB); and Genevieve Marie Catherine Labbé, Oxford (GB)
Assigned to SpyBiotech Limited, Oxford (GB)
Appl. No. 17/052,707
Filed by SpyBiotech Limited, Oxford (GB)
PCT Filed May 3, 2019, PCT No. PCT/GB2019/051245 § 371(c)(1), (2) Date Nov. 3, 2020, PCT Pub. No. WO2019/211630, PCT Pub. Date Nov. 7, 2019.
Claims priority of application No. 1807376 (GB), filed on May 4, 2018; and application No. 1807378 (GB), filed on May 4, 2018.
Prior Publication US 2021/0128717 A1, May 6, 2021
Int. Cl. A61K 39/245 (2006.01); A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61P 31/22 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); A61P 31/14 (2018.01); A61P 31/22 (2018.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); C12N 2710/16123 (2013.01); C12N 2710/16134 (2013.01); C12N 2760/18523 (2013.01); C12N 2760/18534 (2013.01)]

15 Claims

1. A composition comprising a virus-like particle displaying an antigenic component, wherein said composition comprises:

i) an antigenic component comprising a first peptide tag, and

ii) a moiety comprising a second peptide tag,

wherein the antigenic component and the moiety are linked via an isopeptide bond between said first and second peptide tags, wherein the antigenic component is over 50 kDa and is a multimer;

wherein the moiety is a surface antigen of the hepatitis B virus (HBsAg) and multimerises to form the virus-like particle;

wherein the first peptide tag is a SpyTag having the amino acid sequence set out in SEQ ID NO: 30; and

wherein the second peptide tag is a SpyCatcher having the amino acid sequence set out in SEQ ID NO: 38.